These are the stocks posting the largest moves in midday trading.
disappointing preliminary results for a phase three trial of a lung cancer treatment.
AstraZeneca said it slowed progression of the cancer, but the data for overall survival was "not mature" and the results were not statistically significant. The trial will continue to assess overall survival with greater maturity, the company said.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
XPeng G6 Releases In China As Budget Tesla Model Y AlternativeXPeng has launched a new crossover starting at the equivalent of under $29,000. in China, dubbed the G6.
Weiterlesen »
Nio, XPeng stocks surge after EV delivery dataShares of China-based electric-vehicle makers surged Monday, after they reported June deliveries that showed big jumps from May.
Weiterlesen »
Shares of Chinese Tesla rival Xpeng rocket 11% as EV deliveries return to growthXpeng said it delivered 23,205 cars in the second quarter of 2023, a 27% quarter-on-quarter rise, beating its own forecasts.
Weiterlesen »
Xpeng G6 Starts At $29,000 In China, Undercuts Tesla Model Y By 20% | CarscoopsThe Xpeng G6 has up to 755 km of range, exceeding that of the Tesla Model Y car auto cars
Weiterlesen »
Stocks making the biggest moves in the premarket: Tesla, Apple, AstraZeneca and moreThese are the stocks posting the largest moves in premarket trading.
Weiterlesen »
Rivian beats estimates for second-quarter R1T and R1S deliveries - AutoblogRivian, which announced in February plans to lay off 6% of its workforce, reiterated its annual production target of 50,000 units.
Weiterlesen »